OBJECTIVE: Little is known about genetic contributors to higher than usual warfarin dose requirements, particularly for African Americans. This study tested the hypothesis that the γ-glutamyl carboxylase (GGCX) genotype contributes to warfarin dose requirements greater than 7.5 mg/day in an African American population. METHODS: A total of 338 African Americans on a stable dose of warfarin were enrolled. The GGCX rs10654848 (CAA)n, rs12714145 (G>A), and rs699664 (p.R325Q); VKORC1 c.-1639G>A and rs61162043; and CYP2C9*2, *3, *5, *8, *11, and rs7089580 genotypes were tested for their association with dose requirements greater than 7.5 mg/day alone and in the context of other variables known to influence dose variability. RESULTS: The GGCX rs10654848 (CAA)16 or 17 repeat occurred at a frequency of 2.6% in African Americans and was overrepresented among patients requiring greater than 7.5 mg/day versus those who required lower doses (12 vs. 3%, P=0.003; odds ratio 4.0, 95% confidence interval, 1.5-10.5). The GGCX rs10654848 genotype remained associated with high dose requirements on regression analysis including age, body size, and VKORC1 genotype. On linear regression, the GGCX rs10654848 genotype explained 2% of the overall variability in warfarin dose in African Americans. An examination of the GGCX rs10654848 genotype in warfarin-treated Caucasians revealed a (CAA)16 repeat frequency of only 0.27% (P=0.008 compared with African Americans). CONCLUSION: These data support the GGCX rs10654848 genotype as a predictor of higher than usual warfarin doses in African Americans, who have a 10-fold higher frequency of the (CAA)16/17 repeat compared with Caucasians.
OBJECTIVE: Little is known about genetic contributors to higher than usual warfarin dose requirements, particularly for African Americans. This study tested the hypothesis that the γ-glutamyl carboxylase (GGCX) genotype contributes to warfarin dose requirements greater than 7.5 mg/day in an African American population. METHODS: A total of 338 African Americans on a stable dose of warfarin were enrolled. The GGCXrs10654848 (CAA)n, rs12714145 (G>A), and rs699664 (p.R325Q); VKORC1 c.-1639G>A and rs61162043; and CYP2C9*2, *3, *5, *8, *11, and rs7089580 genotypes were tested for their association with dose requirements greater than 7.5 mg/day alone and in the context of other variables known to influence dose variability. RESULTS: The GGCXrs10654848 (CAA)16 or 17 repeat occurred at a frequency of 2.6% in African Americans and was overrepresented among patients requiring greater than 7.5 mg/day versus those who required lower doses (12 vs. 3%, P=0.003; odds ratio 4.0, 95% confidence interval, 1.5-10.5). The GGCXrs10654848 genotype remained associated with high dose requirements on regression analysis including age, body size, and VKORC1 genotype. On linear regression, the GGCXrs10654848 genotype explained 2% of the overall variability in warfarin dose in African Americans. An examination of the GGCXrs10654848 genotype in warfarin-treated Caucasians revealed a (CAA)16 repeat frequency of only 0.27% (P=0.008 compared with African Americans). CONCLUSION: These data support the GGCXrs10654848 genotype as a predictor of higher than usual warfarin doses in African Americans, who have a 10-fold higher frequency of the (CAA)16/17 repeat compared with Caucasians.
Authors: V C De Oliveira Almeida; A C De Souza Ferreira; D D Ribeiro; K B Gomes Borges; A P Salles Moura Fernandes; A L Brunialti Godard Journal: J Thromb Haemost Date: 2011-10 Impact factor: 5.824
Authors: Mitchell K Higashi; David L Veenstra; L Midori Kondo; Ann K Wittkowsky; Sengkeo L Srinouanprachanh; Fred M Farin; Allan E Rettie Journal: JAMA Date: 2002-04-03 Impact factor: 56.272
Authors: M Wadelius; K Sörlin; O Wallerman; J Karlsson; Q-Y Yue; P K E Magnusson; C Wadelius; H Melhus Journal: Pharmacogenomics J Date: 2004 Impact factor: 3.550
Authors: Elaine M Hylek; Alan S Go; Yuchiao Chang; Nancy G Jensvold; Lori E Henault; Joe V Selby; Daniel E Singer Journal: N Engl J Med Date: 2003-09-11 Impact factor: 91.245
Authors: Simone Rost; Andreas Fregin; Vytautas Ivaskevicius; Ernst Conzelmann; Konstanze Hörtnagel; Hans-Joachim Pelz; Knut Lappegard; Erhard Seifried; Inge Scharrer; Edward G D Tuddenham; Clemens R Müller; Tim M Strom; Johannes Oldenburg Journal: Nature Date: 2004-02-05 Impact factor: 49.962
Authors: Simone Rost; Andreas Fregin; Dieter Koch; Markus Compes; Clemens R Müller; Johannes Oldenburg Journal: Br J Haematol Date: 2004-08 Impact factor: 6.998
Authors: Katarzyna Drozda; Yana Labinov; Ruixuan Jiang; Margaret R Thomas; Shan S Wong; Shitalben Patel; Edith A Nutescu; Larisa H Cavallari Journal: Am J Pharm Educ Date: 2013-10-14 Impact factor: 2.047
Authors: Laura K Wiley; Jacob P Vanhouten; David C Samuels; Melinda C Aldrich; Dan M Roden; Josh F Peterson; Joshua C Denny Journal: Pac Symp Biocomput Date: 2017
Authors: Nita A Limdi; Todd M Brown; Qi Yan; Jonathan L Thigpen; Aditi Shendre; Nianjun Liu; Charles E Hill; Donna K Arnett; T Mark Beasley Journal: Blood Date: 2015-05-29 Impact factor: 22.113